A Randomized Double-Blind Phase 2 Study Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications

Trial Profile

A Randomized Double-Blind Phase 2 Study Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Amantadine (Primary) ; Oseltamivir (Primary) ; Ribavirin (Primary)
  • Indications Influenza virus infections
  • Focus Therapeutic Use
  • Acronyms IRC003
  • Most Recent Events

    • 01 Dec 2017 Primary endpoint of Percentage of participants with virus detectable by quantitative PCR in nasopharyngeal swabs at day 3 has been met, according to results published in The Lancet Infectious Diseases.
    • 01 Dec 2017 Results published in The Lancet Infectious Diseases
    • 31 Jan 2017 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top